AS OF 10 /28/22
ONE YEAR 79.67 % DOWN
3MONTHS 9.97 % GAIN
1 MONTH 42.38 % GAIN
ONE WEEK 9.97 %
| ID | STOCK | REMARK PRICE | BROKER | DATE AND TIME | PRICES | AMOUNT | Field1 | number | fill prices | fill dollar | total filled | total unit | average | NET LOSS | Field2 | REMARK |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 294 | ABEO | TD | 10/28/2022 | $4.25 | 2 | $8.49 | 0 | $0.00 | $0.00 | $8.49 | 2 | $4.25 | 0 |
AS OF 10 /28/22
ONE YEAR 79.67 % DOWN
3MONTHS 9.97 % GAIN
1 MONTH 42.38 % GAIN
ONE WEEK 9.97 %
| ID | STOCK | REMARK PRICE | BROKER | DATE AND TIME | PRICES | AMOUNT | Field1 | number | fill prices | fill dollar | total filled | total unit | average | NET LOSS | Field2 | REMARK |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 294 | ABEO | TD | 10/28/2022 | $4.25 | 2 | $8.49 | 0 | $0.00 | $0.00 | $8.49 | 2 | $4.25 | 0 |
To buy in RH
1:59p ET 8/11/2022 - Benzinga
Price
| Mentioned: | ABEO |
SVB Leerink analyst Mani Foroohar maintains Abeona Therapeutics (NASDAQ:ABEO) with a Market Perform and raises the price target from $1 to $5.
Latest Ratings for ABEO DateFirmActionFromTo
Nov 2021SVB LeerinkDowngradesOutperformMarket Perform Nov 2021HC Wainwright & Co.MaintainsBuy Jul 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for ABEO
View the Latest Analyst Ratings
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
| ID | stock | broker | amount | AVG | BUY TOTAL | date | time | Filled price | amount filled | volume | Total filled | total Stock | Total $ | final price | Remark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | ABEO | TH | 4 | $5.35 | $21.40 | 8/5/2022 | $4.20 | 200.00 | 0 | $840.00 | 204 | $861.40 | $4.22 |
